Sonja A Å elemetjev

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3783508/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Focal adhesion kinase splicing and protein activation in papillary thyroid carcinoma progression. Histochemistry and Cell Biology, 2022, 157, 183-194.	1.7	8
2	Novel approach to the measurement of antithyroglobulin antibodies in human serum – application of the quartz crystal microbalance sensors. Talanta, 2021, 223, 121588.	5.5	6
3	Elevated BANCR expression levels have different effects on papillary thyroid carcinoma progression depending on the presence of the BRAFV600E mutation. European Journal of Surgical Oncology, 2020, 46, 1835-1842.	1.0	6
4	Coexistence of BRAFV600E mutation and EGFR overexpression is highly associated with adverse clinicopathological features of papillary thyroid carcinoma. Archives of Biological Sciences, 2020, 72, 37-44.	0.5	0
5	MMP-9-1562 C/T single nucleotide polymorphism associates with increased MMP-9 level and activity during papillary thyroid carcinoma progression. Pathology, 2019, 51, 55-61.	0.6	15
6	Overexpression of epidermal growth factor receptor and its downstream effector, focal adhesion kinase, correlates with papillary thyroid carcinoma progression. International Journal of Experimental Pathology, 2018, 99, 87-94.	1.3	15
7	High expression and localization of β-catenin and epidermal growth factor receptor identify high risk papillary thyroid carcinoma patients. Experimental and Molecular Pathology, 2018, 105, 181-189.	2.1	6
8	Concomitant high expression of survivin and vascular endothelial growth factor-C is strongly associated with metastatic status of lymph nodes in papillary thyroid carcinoma. Journal of Cancer Research and Therapeutics, 2018, 14, S114-S119.	0.9	14
9	Coexpressed High Levels of VEGF-C and Active MMP-9 Are Associated With Lymphatic Spreading and Local Invasiveness of Papillary Thyroid Carcinoma. American Journal of Clinical Pathology, 2016, 146, 594-602.	0.7	24
10	Changes in the expression pattern of apoptotic molecules (galectin-3, Bcl-2, Bax, survivin) during progression of thyroid malignancy and their clinical significance. Wiener Klinische Wochenschrift, 2015, 127, 337-344.	1.9	18
11	Strong Expression of HBME-1 Associates with High-Risk Clinicopathological Factors of Papillary Thyroid Carcinoma. Pathology and Oncology Research, 2015, 21, 735-742.	1.9	6
12	Enhanced activation of matrix metalloproteinase-9 correlates with the degree of papillary thyroid carcinoma infiltration. Croatian Medical Journal, 2014, 55, 128-137.	0.7	31
13	Evaluation of survivin expression and its prognostic value in papillary thyroid carcinoma. Pathology Research and Practice, 2014, 210, 30-34.	2.3	13
14	Survivin in relation to Bcl-2, Bax and in situ apoptotic cell death in anaplastic thyroid carcinoma. Archives of Biological Sciences, 2011, 63, 955-963.	0.5	0
15	Apoptosis and proliferation related molecules (Bcl-2, Bax, p53, PCNA) in papillary microcarcinoma versus papillary carcinoma of the thyroid. Pathology, 2008, 40, 475-480.	0.6	21